Skip to main content
Caplight Logo









AL-S Pharma AG

AL-S Pharma AG

Private
SchlierenHealthcare & Life Scienceshttps://al-spharma.com/

Last Round

VC Round

Dec 7, 2016

Company Overview

AL-S Pharma AG is a clinical-stage biotechnology company developing AP-101, an antibody therapeutic for the treatment of amyotrophic lateral sclerosis (ALS).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

ALS therapeuticamyotrophic lateral sclerosismonoclonal antibodyclinical stage biotechSOD1 targetALSmAbsingle-asset companydisease-modifying therapybuild-to-buy biotechneurodegenerative diseaseantibody therapeuticPhase 2 clinical trialsuperoxide dismutase 1special purpose company

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AL-S Pharma AG Comparables

Compare AL-S Pharma AG with similar companies based on industry and business-model similarity.

AL-S Pharma AG comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Axoltis Pharma
78%
Prilenia Therapeutics
78%
QurAlis
77%

AL-S Pharma AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundDec 7, 2016

AL-S Pharma AG Investors

Notable investors and investment history

AL-S Pharma AG investors
InvestorRounds
TVM CapitalVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 7, 2016

    Raised capital from TVM Capital and Neurimmune AG.

AL-S Pharma AG Filings

Explore SEC and related filing metadata, where available.

AL-S Pharma AG filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about AL-S Pharma AG's valuation, stock price, and market status.

Is AL-S Pharma AG a public or private company?

AL-S Pharma AG is a private company.

What is the current stock price of AL-S Pharma AG?

AL-S Pharma AG is a private company with no public stock price. No recent secondary market data is available.

How much is AL-S Pharma AG worth (valuation)?

Valuation information for AL-S Pharma AG is not publicly available.

Can I buy AL-S Pharma AG stock?

AL-S Pharma AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was AL-S Pharma AG's last funding round?

AL-S Pharma AG's most recent funding round was VC Round on December 7, 2016.

Who are the main investors in AL-S Pharma AG?

Key investors in AL-S Pharma AG include TVM Capital.

Will AL-S Pharma AG IPO soon?

No public IPO plans have been announced for AL-S Pharma AG.

How can I track AL-S Pharma AG secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AL-S Pharma AG's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSchlieren
Year Founded2016
Last FundingDec 7, 2016

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?